Categories AlphaGraphs, Earnings, Health Care
Earnings: Highlights of Eli Lilly & Company’s (LLY) Q1 2023 results
Eli Lilly and Company (NYSE: LLY) on Thursday reported lower earnings and revenues for the first quarter of 2023. The company also provided guidance for fiscal 2023.
The Indianapolis-based pharmaceutical company said its revenues declined 11% year-over-year to $6.96 billion in the first quarter, hurt by lower realized prices and a decline in volumes.
The weak top-line performance translated into a 38% fall in net earnings, on an adjusted basis, to $1.62 per share. Unadjusted profit decreased to $1.34 billion or $1.49 per share from $1.90 billion or $2.10 per share in the first quarter of 2022.
“Core business growth drove solid first-quarter financial results and a strong start for Lilly in 2023, which includes pipeline progress led by positive SURMOUNT-2 data for tirzepatide in obesity,” said David Ricks, CEO of Eli Lilly.
Prior Performance
Most Popular
Lamb Weston (LW) Q2 2026 Earnings: Key financials and quarterly highlights
Lamb Weston Holdings, Inc. (NYSE: LW) reported its second quarter 2026 earnings results today. Net sales inched up 1% year-over-year to $1.62 billion. Net sales at constant currency remained flat.
Paychex reports higher Q2 FY26 revenue and earnings; EPS beats estimates
Paychex Inc. (NASDAQ: PAYX) on Friday reported stronger-than-expected adjusted earnings for the second quarter of fiscal 2026. Revenues grew 18% year-over-year. The Rochester-based human capital management solutions provider reported revenues
Key highlights from NIKE’s (NKE) Q2 2026 earnings results
NIKE, Inc. (NYSE: NKE) reported revenues of $12.4 billion for the second quarter of 2026, which were up 1% on a reported basis and flat on a currency-neutral basis compared
